Laropiprant
General information:
| Withdrawn ID: | DB11629 |
|---|---|
| Canonical SMILES: | |
| Standard InChI: | |
| Standard InChIKey: | |
| Molecular Formula: | C21H19ClFNO4S |
| Molweight: | 435.89 |
Withdrawal information:
| Withdrawn due to drug safety reasons: | Yes |
|---|---|
| First withdrawn: | 2013 |
| Reference: | https://www.ema.europa.eu/en/news/european-medicines-agency-confirms-recommendation-suspend-tredaptive-pelzont-trevaclyn |
Filtered ChEMBL targets:
| Target UniProtKB ID | Activity in nm | Target Name | Target gene |
|---|---|---|---|
| P21731 | 2.95 | Thromboxane A2 receptor | TA2R_HUMAN |
| P34995 | 1160 | Prostaglandin E2 receptor EP1 subtype | PE2R1_HUMAN |
| P43088 | 9991 | Prostaglandin F2-alpha receptor | PF2R_HUMAN |
| P43115 | 892 | Prostaglandin E2 receptor EP3 subtype | PE2R3_HUMAN |
| P43116 | 136 | Prostaglandin E2 receptor EP2 subtype | PE2R2_HUMAN |
| P43119 | 6628 | Prostacyclin receptor | PI2R_HUMAN |
| Q13258 | 0.03 | Prostaglandin D2 receptor | PD2R_HUMAN |
| Q9Y5Y4 | 745 | Prostaglandin D2 receptor 2 | PD2R2_HUMAN |
Toxicity information:
External links:
| ChEBML: | CHEMBL426559 |
|---|